| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA2413137
Max Phase: Preclinical
Molecular Formula: C26H24Cl2FN3O2S
Molecular Weight: 532.47
Molecule Type: Small molecule
Associated Items:
Representations
Canonical SMILES: CN(C)CCN(Cc1ccc(Cl)c(Cl)c1)C(=O)c1c(-c2ccc(F)cc2)c2cscc2c(=O)n1C
Standard InChI: InChI=1S/C26H24Cl2FN3O2S/c1-30(2)10-11-32(13-16-4-9-21(27)22(28)12-16)26(34)24-23(17-5-7-18(29)8-6-17)19-14-35-15-20(19)25(33)31(24)3/h4-9,12,14-15H,10-11,13H2,1-3H3
Standard InChI Key: MYQLEVJUCWDMNT-UHFFFAOYSA-N
Associated Targets(Human)
Centromere-associated protein E 102 Activities
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 532.47 | Molecular Weight (Monoisotopic): 531.0950 | AlogP: 5.92 | #Rotatable Bonds: 7 |
| Polar Surface Area: 45.55 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 0 |
| #RO5 Violations: 2 | HBA (Lipinski): 5 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 2 |
| CX Acidic pKa: | CX Basic pKa: 8.46 | CX LogP: 5.12 | CX LogD: 4.03 |
| Aromatic Rings: 4 | Heavy Atoms: 35 | QED Weighted: 0.30 | Np Likeness Score: -1.45 |
References
| 1. Hirayama T, Okaniwa M, Imada T, Ohashi A, Ohori M, Iwai K, Mori K, Kawamoto T, Yokota A, Tanaka T, Ishikawa T.. (2013) Synthetic studies of centromere-associated protein-E (CENP-E) inhibitors: 1.Exploration of fused bicyclic core scaffolds using electrostatic potential map., 21 (17): [PMID:23816042] [10.1016/j.bmc.2013.05.067] |
Source
Source(1):